3 results
Primary objective: to determine the biological activityof Hespecta that is able to induce HPV16 E6-specific T-cell immunity within a proposed dose escalation of 1, 5, 20 or 50 µg/peptide - conjugate in patients treated for HPV16+ OSCC.Secondary…
Primary ObjectiveTo demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS or OS in the first-line treatment of PD-L1 positive patients with aRCC.Secondary Objectives* To demonstrate that…
The purpose of this study is to separately evaluate 2 agents with different mechanisms of action that may be effective in subjects with low-risker MDS. The design of this study will allow an unbiased assessment of which agent, if either, will…